DBVT logo

DBV Technologies S.A.


DBVT: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.


Show DBVT Financials

Consumer Interest
SEC Filings

Recent trades of DBVT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by DBVT's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Allergen desensitization method Dec. 21, 2021
  • Patent Title: Compositions of food allergens Jan. 05, 2021
  • Patent Title: Allergen desensitization method Sep. 01, 2020
  • Patent Title: Compositions for delivery of food allergens to the stomach May. 28, 2019
  • Patent Title: Allergen desensitization method Apr. 30, 2019
  • Patent Title: Allergen desensitization method Jul. 17, 2018
  • Patent Title: Allergen desensitization method Jan. 10, 2017
  • Patent Title: Method and compositions for cutaneous immunisation Mar. 03, 2015
  • Patent Title: Method of treating eosinophilic esophagitis Jan. 13, 2015
  • Patent Title: Device for the cutaneous application of substances Nov. 05, 2013
  • Patent Title: Patch for cutaneous application Oct. 16, 2012
  • Patent Title: Immunotherapeutic method for increasing groundnut tolerance in a subject Jun. 19, 2012
  • Patent Title: Patch for screening and sensitization state of a subject with respect to an allergen and use thereof May. 25, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of DBVT in WallStreetBets Daily Discussion


Recent insights relating to DBVT

CNBC Recommendations

Recent picks made for DBVT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in DBVT

Corporate Flights

Flights by private jets registered to DBVT